News | July 22, 2023
Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
The company has reported total income of Rs. 604.02 crores during the period ended March 31, 2023
Mandaviya felicitated voluntary blood donors and states/UTs that have done exemplary work
Despite the technological advancements, there remains no alternative to blood and one unit of blood can save as many as three lives
The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
Technology Development Board supports commercialisation of Metal Injection Molding of implants
Subscribe To Our Newsletter & Stay Updated
